This study is for people who have had a living-donor liver transplant and want to stop taking immunosuppressant medications. These medications are usually needed for life but can have serious side effects. Researchers are testing a new approach where you receive a special infusion of donor hematopoietic stem and progenitor cells (HSPCs) from your original liver donor. Before the infusion, you will have a two-week conditioning treatment. The goal is to retrain your immune system to accept your new liver without the need for daily medication. The study will measure how many people can successfully stop their immunosuppressants, specifically tacrolimus, 12 months after the HSPC infusion. You may be eligible if you are 18 or older and received a liver from a living donor with a good HLA match.

Study design

This is an interventional study with a planned enrollment of 12 participants. It involves a single treatment arm where all participants receive the donor HSPC infusion.

What's involved

You will undergo a two-week conditioning regimen followed by the HSPC infusion, all in an outpatient setting. Graft function, chimerism, and protocol biopsies will be monitored at various times, and attempts will be made to discontinue tacrolimus.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured at 12 months after the HSPC infusion, with tacrolimus weaning planned to begin at 6 months and discontinuation by 10-12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.